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Background. Whether antibiotic treatment of asymptomatic bacteriuria (AB) can prevent acute graft pyelonephritis (AGP) in 
kidney transplant (KT) recipients has not been elucidated.
Methods. In this multicenter, open-label, nonblinded, prospective, noninferiority, randomized controlled trial, we compared 
antibiotic treatment with no treatment for AB in KT recipients in the first year after transplantation when urinary catheters had been 
removed. The primary endpoint was the occurrence of AGP. Secondary endpoints included bacteremic AGP, cystitis, susceptibility 
of urine isolates, graft rejection, graft function, graft loss, opportunistic infections, need for hospitalization, and mortality.
Results. We enrolled 205 KT recipients between 2013 and 2015. AB occurred in 41 (42.3%) and 46 (50.5%) patients in the 
treatment and no treatment groups, respectively. There were no differences in the primary endpoint in the intention-to-treat popu-
lation (12.2% [5 of 41] in the treatment group vs 8.7% [4 of 46] in the no treatment group; risk ratio, 1.40; 95% confidence interval, 
0.40–4.87) or the per-protocol population (13.8% [4 of 29] in the treatment group vs 6.7% [3 of 45] in the no treatment group; risk 
ratio, 2.07, 95% confidence interval, 0.50–8.58). No differences were found in secondary endpoints, except for antibiotic suscepti-
bility. Fosfomycin (P = .030), amoxicillin-clavulanic (P < .001) resistance, and extended-spectrum β-lactamase production (P = .044) 
were more common in KT recipients receiving antibiotic treatment for AB.
Conclusions. Antibiotic treatment of AB was not useful to prevent AGP in KT recipients and may increase antibiotic resistance. 
However, our findings should be regarded with caution, due to the small sample size analyzed.
Key words. asymptomatic bacteriuria; kidney transplantation; pyelonephritis.
INTRODUCTION
Urinary tract infection is the most common complication in 
kidney transplant (KT) recipients, notably in the first months after 
KT, with an incidence that varies from 6% to 83% depending on 
whether symptomatic or asymptomatic infections are considered 
[1–5]. The most serious manifestation is acute graft pyelone-
phritis (AGP), which is the leading cause of bacteremia in this 
population and is often complicated by acute graft dysfunction 
requiring hospitalization [6, 7]. Cytomegalovirus (CMV) infec-
tion, rejection, chronic allograft dysfunction, and mortality have 
also been associated with AGP in some studies [4, 5, 8–11].
Infections due to multidrug-resistant (MDR) organisms have 
become a serious problem in KT recipients [12] because of their 
association with higher complication and recurrences rates [13, 
14]. Moreover, MDR infections require treatment with last re-
sort antibiotics that are usually associated with more adverse 
events, including nephrotoxicity, which may be increased by the 
concomitant use of calcineurin inhibitors [15]. Given this wor-
risome scenario, effective strategies of antibiotic stewardship are 
urgently needed to reduce resistance rates while maintaining 
patient safety. When considering this, however, it is important 
that we acknowledge the key role of antibiotic pressure as the 
major driver for the selection of MDR bacteria.
Measures are needed to prevent AGP after KT, and the po-
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bacteriuria (AB) remains controversial [16, 17]. At present, the 
management of AB in KT recipients varies between transplant 
centers [18] and due to a lack of solid evidence [19–22]. However, 
recently published guidelines provide recommendations against 
screening and treating AB episodes after KT, especially within the 
first month following KT [23, 24]. Moreover, a randomized trial 
found no apparent benefit from screening and treating AB in 112 
KT recipients beyond the second month after transplantation [25].
In this multicenter, randomized controlled trial (RCT), we aimed 
to test the hypothesis that no treatment for AB in KT recipients would 
be noninferior to antibiotic treatment in the prevention of AGP.
METHODS
Design and Study Endpoints
This prospective, multicenter, open-label, nonblinded, 
noninferiority RCT was conducted from January 2013 to 
September 2015. We compared the efficacies of antibiotic treat-
ment and no treatment of AB to prevent AGP in KT recipients 
during the first year posttransplantation and after urinary 
catheters removal. The primary study endpoint was the in-
cidence of the first episode of AGP. Secondary endpoints in-
cluded AGP-related bacteremia, cystitis, acute graft rejection, 
opportunistic infections, hospitalization due to any cause, graft 
function, graft loss, mortality, and antimicrobial susceptibility 
of microorganisms isolated in urine cultures.
Setting and Study Population
The study was performed centrally in 2 university hospitals 
with active renal transplant programs in Barcelona. Patients 
were identified at each participating hospital by checking daily 
if a KT had been performed. Consecutive KT recipients were 
eligible for enrolment if they were aged 18 years or older, had 
received a KT in the previous month, and if they or their legal 
surrogate provided written informed consent. Patients were 
excluded from inclusion if they were already included in another 
clinical trial in which the treatment of AB was recommended or 
if they did not provide informed consent.
Randomization and Allocation Concealment
Randomization was performed by computer-generated random 
code allocation with a block size of ten. The program randomly 
assigned participants on a 1:1 basis to 2 parallel groups in 2 treat-
ment arms, stratified by hospital site. A  biostatistician held the 
random code centrally. One investigator in each hospital opened 
the sealed and sequentially numbered opaque envelopes for the 
randomly assigned patients who had provided written informed 
consent and met the study criteria. No attempt was made to conceal 
study arm intervention from patients or treating clinicians.
Intervention
Patients fulfilling the inclusion requirements were randomly 
assigned to receive antibiotic treatment or no treatment when 
AB was documented. If AB occurred during follow-up, anti-
biotic treatment was prescribed for 5–7 days according to the 
susceptibility of the microorganism isolated in urine culture. 
If fosfomycin was used, a shorter antibiotic course of 1–3 days 
was considered appropriate. To avoid the interference of foreign 
bodies, study interventions only began when urethral and ure-
teral catheters had been removed. From KT to removal of uri-
nary catheters, the decision whether to treat AB with antibiotics 
was made by the attending physician.
Follow-up and Outcomes Assessments
Clinical follow-up was performed by transplant physicians 
in outpatient settings at the following posttransplantation 
intervals: weekly in the first month, every 2 weeks from the 
second to third month, once monthly from the third to sixth 
month, and every 3 months from the sixth to the twelfth month. 
It was ensured that essential data about outcomes were regis-
tered and that all necessary urinary and blood samples were col-
lected and analyzed. If the patients required other medical visits 
or needed hospitalization, the investigators evaluated them and 
relevant data were collected.
Urine cultures and blood analysis of graft function were 
done at every follow-up visit, plus when the attending physi-
cian considered testing necessary. Quantitative urine cultures 
were analyzed in cystine lactose electrolyte deficient agar with 
a 0.001 mL calibrated loop. Antibiotic susceptibility of isolated 
microorganisms was assessed by the disk-diffusion method, 
and the minimum inhibitory concentration was determined. 
If urine cultures were contaminated, they were considered 
negative and not repeated. Urine cultures were performed if 
symptoms of urinary infection were present, and blood cultures 
were performed if AGP was suspected clinically.
To evaluate the primary endpoint, all episodes of AGP during fol-
low-up were carefully evaluated and recorded. Secondary endpoints 
also were registered. For all episodes of AB, isolated organisms and 
antibiotic susceptibilities were recorded. All antibiotics prescribed 
in patients assigned to the antibiotic group were recorded.
Definitions
AB was considered present if a patient without symptoms pro-
vided a single, clean-catch voided urine specimen with 1 bac-
terial isolate present at ≥105 colony-forming units/mL. Cystitis 
was diagnosed if bacteriuria was present with symptoms of 
dysuria, frequency, and urinary urgency, without meeting the 
criteria for AGP. Acute graft pyelonephritis was defined by the 
simultaneous presence of fever with bacteriuria or bacteremia, 
or both, and 1 or more of the following: renal allograft tender-
ness, chills, or criteria for cystitis [21]. Contaminated urine 
culture was defined as a culture of urinary sample that grows 
3 or more different types of bacteria. Allograft rejection was 
diagnosed based on impaired renal function with suggestive 
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function necessitating chronic dialysis. Opportunistic infection 
was considered when any infection due to an opportunistic 
pathogen occurred during study follow-up (ie, CMV, BK virus). 
Hospitalization was defined as any hospital admission due to 
causes other than AGP. Mortality was defined as death due to 
any cause during study follow-up.
Exclusion Criteria Before Trial Intervention
We excluded patients with graft loss or who were lost to fol-
low-up before urinary catheters were removed, as well as 
patients with surgical complications that prolonged the need 
for urinary catheters. KT recipients without documented AB 
during follow-up also were excluded.
Statistical Analysis
The sample size was estimated based on the hypothesis that no 
treatment would be noninferior to antibiotic treatment at affecting 
the incidence of AGP in KT recipients with AB. The required 
sample size was estimated for a noninferiority of 15% between 
the 2 management strategies and a probability that AGP would 
occur in 20%. This indicated that 100 patients would be neces-
sary per group to achieve an estimated power of 65.8%, allowing 
for the likelihood that 40% of randomized patients would be 
excluded for not presenting with AB or for other reasons.
Data were collected and anonymously entered in a dedicated 
database that was reviewed periodically by descriptive analysis 
to detect illogical data. The baseline characteristics and outcome 
measures were compared by the χ2 test for categorical variables 
and t test or nonparametric Mann-Whitney test for contin-
uous variables, as appropriate. Noninferiority was defined as 
the upper limit of the 1-sided, 97.5% confidence interval (CI) 
of the difference in the incidence of AGP in KT recipients be-
tween study groups being <15%. All statistical analyses were 
performed with R (version 3.4.1 for Windows).
The intention-to-treat (ITT) population was defined as KT 
recipients who developed AB within 12 months of follow-up after 
urethral and ureteral catheter removal. The per-protocol (PP) 
population comprised the ITT population that received antibiotic 
treatment or no treatment for AB according to randomization.
Ethical Issues
This trial is registered with the US National Library of Medicine at 
https://clinicaltrials.gov/ as study number NCT01771432 and was 
conducted according to the principles of the Declaration of Helsinki 
(2008) and current Spanish legislation (Real decreto 223/2004). The 
principal investigator or collaborator at each site obtained written 
informed consent from all patients (or legal representatives if they 
lacked capacity) before enrollment. The study data were identified 
by a code, maintaining patient confidentiality in accordance with 
current legislation. The trial protocol, the informed consent form, 
and information sheet received research ethics committee approval. 
Clinical trial authorization was granted by the Spanish Agency for 
Medicines and Health Products. In accordance with Spanish legisla-
tion governing clinical trials (RD 223/2004), this study had liability 
insurance covering possible damages to patients during their partic-




The flow chart for study inclusion is shown in Figure 1. In total, 
402 KTs were performed in the participating hospitals during 
the study period. Among these, 205 KT recipients were enrolled 
in the study and underwent randomization, wherein 102 were 
assigned to the antibiotic treatment group and 103 were assigned 
to the no treatment group. The median time from KT to study 
inclusion was 4  days (interquartile range [IQR] 3–7). Before 
protocol intervention, a further 17 KT recipients were excluded 
for different reasons. All of these patients were excluded early 
after KT and before urinary catheters were removed. Among 
the remaining 188 KT recipients, AB did not occur in 101 
during follow-up (53.7%), so these were also excluded.
ITT and PP Populations
During the 12 month follow-up period, AB was documented in 
41 patients in the antibiotic treatment group and in 46 patients in 
the no treatment group. The median follow-up from the first ep-
isode of AB in the ITT population was 302 days (IQR 244–321.5) 
in antibiotic treatment group and 277 days (IQR 226.5–329) in 
no treatment group, while in the PP population it was 308 days 
(IQR 223–323) in antibiotic treatment group and 281 days (IQR 
226–330) in no treatment group. The median time between KT 
and the first episode of AB was 58 days (IQR 46–121) in anti-
biotic treatment group and 68  days (IQR 44.75–117.25) in no 
treatment group. In the PP population, the mean days between 
KT and the first episode of AB was 53 days (IQR 44.5–117.5) in 
antibiotic treatment group and 68 days (IQR 44.5–113) in the no 
treatment group of AB. The baseline characteristics of the ITT 
populations were comparable and are detailed in Table 1. In 12 
KT recipients assigned to receive antibiotic treatment, no antibi-
otic was prescribed despite AB being identified; also, a single KT 
recipient assigned to the no treatment group received antibiotic 
therapy when AB was present. Consequently, the PP population 
included 29 KT recipients in the antibiotic treatment group and 
45 KT recipients in the no treatment group. No differences were 
found in baseline characteristics of the PP population.
Urine Cultures
In the ITT population, the mean number of urine cultures 
obtained per KT recipient with AB was 7.5 and 7.8 in the an-
tibiotic treatment and no treatment groups, respectively. The 
mean number of positive urine cultures was comparable in each 
group with AB (2.7 in the antibiotic treatment group and 2.8 
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each group had 2 or more episodes of AB during follow-up. The 
mean number of contaminated urine cultures obtained per KT 
recipient in the ITT population was 1.1 in the antibiotic treat-
ment group and 1.5 in the no treatment group. In the ITT pop-
ulation, 114 episodes of AB were documented in the treatment 
group and 77 (67.5%) were treated with antibiotics. In the no 
treatment group, 129 episodes of AB occurred and 4 (3.1%) of 
them were treated with antibiotics.
In the PP population, the success rate in clearing AB in anti-
biotic treatment group was 36.2% (25 of 69 episodes) and 45.7% 
(38 of 83 episodes) in no treatment group, excluding urine 
cultures performed in the twelfth month after KT as no screening 
urine cultures were performed thereafter. Considering all AB 
episodes, independently of the group assigned, the success rate 
in clearing AB was 34.2 % (25 of 73 episodes) in AB episodes 
treated with antibiotics and 46.9% (54 of 115 episodes) in those 
without antibiotic treatment.
In the ITT population prior to ureteral catheter removal, 
25 KT recipients in the treatment group had 40 episodes of 
AB and 24 KT recipients in the no treatment group had 38 
402 Kidney transplant recipients assessed for
eligibility
205 randomized
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Frequent antibiotic use due to
respiratory infection 1
No asymptomatic bacteriuria
occurred during follow up 45




Declined to participate 40
Graft loss 36
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episodes of AB. Antibiotic treatment was prescribed in 45% (18 
of 40) episodes of AB in the treatment group and in 47% (18 of 
38)  episodes of AB in the no treatment group before urinary 
catheters were removed.
Primary Endpoint
In the PP analysis, the number of patients with AGP was 4 
of 29 in the treated group and 3 of 45 in the untreated group. 
The difference in the AGP incidence was 7.13% (97.5% CI, 
-7.39%–21.64%). In intention to treat analysis results were 
similar with a difference in the AGP incidence of 3.50% 
(97.5% CI, -9.40%–16.41%) (Tables 2 and 3). Prior AB due to 
the microorganism that caused AGP occurred in 7 episodes in 
the ITT population (4 of 6 in the antibiotic treatment group 
and 3 of 6 in the no treatment group) and 5 episodes in the 
PP population (3 of 5 in the treatment group and 2 of 4 in the 
no treatment group). Characteristics of AGP episodes are de-
tailed in Table 4.
Table 1. Baseline Characteristics in Intention-to-Treat Population
 
Antibiotic Treatment of Asymptomatic 
Bacteriuria n = 41
No Treatment of Asymptomatic 
Bacteriuria n = 46
n % n %
Male sex 15 36.6 21 45.7
Age, years, mean ± SD 61.048 ± 11.582  60.194 ± 11.412  
Type of donor     
Living donor 10 24.4 6 13.0
Decreased donor 31 75.6 40 87.0
Etiology of renal impairment     
Unknown 7 17.1 12 26.1
Diabetic nephropathy 9 22.0 8 17.4
Kidney polycystic disease 5 12.2 9 16.9
Glomerulonephritis 6 14.6 7 15.2
Nephroangiosclerosis 4 9.8 2 4.3
Other 10 24.4 8 17.4
Previous kidney transplant 11 26.8 7 15.2
Diabetes mellitus     
Before kidney transplant 10 24.4 13 28.3
After kidney transplant 7 17.1 5 10.9
Preemptive transplant 8 19.5 6 13.0
Previous hemodialysis 30 73.0 34 73.9
Previous peritoneal dialysis 3 7.3 6 13.0
Months in dialysis, mean ± SD 31.900 ± 36.848  24.181 ± 30.801  
Donor positive/recipient negative CMV serostatus 1 2.4 5 10.9
Complications during admission after kidney transplant 22 53.7 24 52.2
Delayed graft function 7 17.9 12 29.3
Reintervention 1 2.6 3 7.3
ICU admission 7 18.4 3 7.3
Acute rejectiona 3 7.3 2 4.3
Days of admission for kidney transplant, mean ± SD 14.926 ± 7.705  12.434 ± 7.960  
Immunosuppressive treatment     
Monoclonal antibodies 15 55.6 23 50.0
Antithymocyte globulin 15 36.6 21 45.7
Plasmapheresis 4 9.8 2 4.3
Intravenous immunoglobulin 8 19.5 6 13.0
Corticosteroids 40 97.5 46 100
Corticosteroids at discharge 40 97.5 43 93.5
Calcineurin inhibitors 40 97.6 45 97.8
Mycophenolate 39 95.1 45 97.8
TMP-SMX prophylaxis 41 100 45 97.8
Days of TMP-SMX prophylaxis, mean ± SD 117.289 ± 54.343  100.069 ± 37.750  
CMV prophylaxis with valganciclovir 22 53.7 25 54.3
Days of bladder catheterization, mean ± SD 8.125 ± 4.303  8.577 ± 4.648  
Days of double-J catheterization, mean ± SD 35.124 ± 7.467  35.065 ± 5.405  
Abbreviations: CMV, cytomegalovirus; ICU, intensive care unit; SD, standard deviation; TMP-SMX, trimethoprim-sulfamethoxazole.
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Secondary Endpoints
Secondary study endpoints in the ITT and PP populations 
are detailed in Tables 2, 3, and Figure 2. During follow-up, no 
differences were found between the 2 populations in the in-
cidence rates of bacteremic AGP or cystitis, in the estimated 
glomerular filtration rates, in the hospital admission rates for 
causes other than AGP, or in the rates of opportunistic infections 
or acute graft rejection. There were no graft losses or deaths.
The incidence of a first episode of symptomatic urinary tract in-
fection in treatment versus no treatment group of AB in the ITT 
population was 10 of 41 (24.3%) versus 7 of 46 (15.2%) (P = .280; 
RR, 1.60; 95% CI, 0.67–3.82) and in the PP population it was 7 








P value RR 95% CIn % n %
Primary endpoint        
KT recipients with acute graft pyelonephritisa 4 13.8 3 6.7 .31 2.07 0.50–8.58
Secondary endpoints        
Bacteremic pyelonephritis 0  2 4.4 .25   
Cystitisb 4 13.8 3 6.7 .31 2.07 0.50–8.58
Opportunistic infections 5 17.2 10 22.2 .77 0.78 0.30–2.04
 Cytomegalovirus infectionc 5 17.2 10 22.2 .77 0.78 0.30–2.04
 BK virus infection 2 6.9 0  .07   
Rejection episodesd 1 3.4 2 4.4 .83 0.78 0.07–8.17
Need for hospital admissione 16 55.8 26 57.8 1 0.95 0.63–1.44
Abbreviations: CI, confidence interval; KT, kidney transplant; RR, risk ratio. 
aOne KT recipient in the antibiotic treatment group and 1 recipient in the nontreatment group had 2 episodes of acute graft pyelonephritis (AGP). The median days from transplantation to 
the first episode of AGP were 63 days in the antibiotic treatment group and 169 days in the nontreatment group.
bTwo KT recipients in the antibiotic treatment group and 1 recipient in the nontreatment group had 2 episodes of cystitis.
cTwo KT recipients in the treatment group and 3 patients in the nontreatment group had 2 episodes of cytomegalovirus (CMV) infection. Antibiotic group (no.): viremia (7) and viral syndrome 
(1); nontreatment group (no.): viremia (10), viral syndrome (1), and digestive disease (1).
dOnly rejection episodes occurring after trial intervention was initiated were considered in this variable.
eAdmission due to AGP is not considered in this variable. Twelve (26.7%) KT recipients in the treatment group and 7 (24.1%) patients in the nontreatment group need 2 or more hospital 
admissions different from episodes of AGP. Antibiotic group (no.): renal biopsy per protocol (13), congestive heart failure (1), renal impairment (4), CMV disease (1), and pneumonia (2). 
Nontreatment group (no.): renal biopsy per protocol (22), congestive heart failure (4), renal impairment (1), CMV disease (1), lymphocele (2), pneumonia (1), and Clostridium difficile colitis (1).





No Treatment if 
Asymptomatic 
Bacteriuria n = 46
P value RR 95% CIn % n %
Primary endpoint        
KT recipients with acute graft pyelonephritisa 5 12.2 4 8.7 .59 1.40 0.40–4.87
Secondary endpoints        
Bacteremic pyelonephritis 1 2.4 3 6.5 .36 0.37 0.036–3.588
 Cystitisb 6 14.6 3 6.5 .215 2.24 0.60–8.40
Opportunistic infections 9 22.0 10 21.7 .98 1.01 0.46–2.24
 Cytomegalovirus infectionc 9 22.0 10 21.7 .98 1.01 0.46-2.24
 BK virus infection 2 4.9 0  .13   
Rejection episodesd 1 2.4 2 4.3 .63 0.56 0.05–5.96
Need for hospital admissione 22 53.7 26 56.5 .83 0.95 0.65–1.39
Abbreviations: CI, confidence interval; KT, kidney transplant; RR, risk ratio. 
aOne KT recipient in the antibiotic treatment group and 2 KT recipients in the nontreatment group had 2 episodes of acute graft pyelonephritis (AGP). The median days from transplantation 
to the first episode of AGP were 61 days in the antibiotic treatment group and 121.5 days in the nontreatment group.
bTwo KT recipients in the antibiotic treatment group and 1 recipient in the nontreatment group had 2 episodes of cystitis.
cTwo KT recipients in the treatment group and 3 patients in the nontreatment group had 2 episodes of cytomegalovirus (CMV) infection. Antibiotic group (no.): viremia (11) and viral syndrome 
(1); nontreatment group (no.): viremia (10), viral syndrome (1), and digestive disease (1).
dOnly rejection episodes occurring after trial intervention was initiated were considered in this variable.
eAdmission due to AGP is not considered in this variable. Twelve (26.1%) KT recipients in the treatment group and 8 (19.5%) patients in the nontreatment group needed 2 or more hospital 
admissions for events other than episodes of AGP. Antibiotic group (no.): renal biopsy per protocol (19), congestive heart failure (2), renal impairment (4), CMV disease (1), lymphocele (1), 
pneumonia (2), and diarrhea (1); nontreatment group (no.): renal biopsy per protocol (22), congestive heart failure (5), renal impairment (1), CMV disease (2), lymphocele (2), pneumonia (1), 
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of 29 (24.1%) versus 6 of 45 (13.3%) (P = .233; RR, 1.81; 95% CI, 
0.68–4.85). We counted 4 episodes of bacteremic AGP in patients 
with previous same-microorganism AB in the ITT population (1 
of 1 in the antibiotic treatment group and 2 of 3 in the no treatment 
group) and 2 episodes in the PP population (0 of 0 in the treatment 
group and 2 of 2 in the no treatment group). As cystitis in patients 
with previous same-microorganism AB, we observed 7 episodes in 
the ITT population (7 of 8 in the antibiotic treatment group and 0 
of 4 in the no treatment group) and 6 episodes in the PP population 








0 1 2 3 4 5 6
Antibiotic treatment of  asymptomatic bacteriuria










0 1 2 3 4 5 6
Antibiotic treatment of  asymptomatic bacteriuria
Non-treatment of  asymptomatic bacteriuria
9 12
Months
Figure 2. Evolution of Estimated Glomerular Filtration Rate During 12-Month Follow-up in Intention-to-Treat and in Per-Protocol Populations  Abbreviation: eGFR, estimated 
glomerular filtration rate mL/min/1.73m2.
Table 4. Characteristics of Acute Graft Pyelonephritis Episodes in Patients Included in the Study
Patient Study Group
AGP due to the  
Previous Microorganism  









1 Antibiotic  
treatment 
Yes Yes 284 No Renal insufficiency
2 Antibiotic  
treatment 
Yes Yes 61 No Renal insufficiency
2 Antibiotic  
treatment
Yes Yes 344 No Renal insufficiency
3 Antibiotic  
treatment 
No   65 No No
4 Antibiotic  
treatment 
No   98 No Renal insufficiency
5a Antibiotic  
treatment 
Yes No 72 Yes No
6 No treatment No  303 No No
6 No treatment No  326 No Renal insufficiency
7 No treatment Yes No 219 Yes Renal insufficiency
8 No treatment Yes No 169 Yes No
9a No treatment  No   74 Yes Renal insufficiency
9a No treatment  Yes Yes 330 No Renal insufficiency
Abbreviations: AB, asymptomatic bacteriuria; AGP, acute graft pyelonephritis.
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The identification and antibiotic susceptibility of 
microorganisms isolated in urine cultures of patients with AB 
are detailed in Table 5 for the ITT and PP populations. The most 
frequent microorganism in each group was Escherichia coli, 
followed by Klebsiella pneumoniae and Enterococcus faecalis. 
The number of KT recipients who experienced an extended-
spectrum beta-lactamase (ESBL)-producing bacteria at some 
point during the study follow-up was 8 (19.5%) in treatment 
group versus 7 (15.2%) in no treatment group of AB in the ITT 
population and 5 (17.2%) in treatment group versus 6 (13.3%) 
in no treatment group of AB in the PP population. When all 
isolates of AB episodes were considered, fosfomycin-resistant 
isolates (22.7% vs 12.4% in the ITT population; P = .030, and 
23.4% vs 10.2% in the PP population; P = .007), ESBL-producing 
Enterobacteriaceae (24.5% vs 13.3% in the ITT population; 
P = .044, and 21.1% vs 11.0% in the PP population; P = .067), 
and amoxicillin-clavulanate resistant Enterobacteriaceae 
(52.1% vs 26.7% in the ITT population; P  <  .001, and 51.3% 
vs 22.0% in the PP population; P < .001) were more common 
in the antibiotic treatment groups in both the ITT and the PP 
populations. (Table 5)
Antibiotic Treatment for Asymptomatic Bacteriuria
The antibiotics prescribed by isolate susceptibility in urine 
cultures are detailed in Table 5 for the ITT and the PP 
populations. No serious adverse reactions were associated with 
any antibiotic prescriptions in patients with AB.
DISCUSSION
In this noninferiority, multicenter RCT of KT recipients with 
AB, we found no significant differences in the incidence of 
AGP in the first year after transplantation between a group 
receiving antibiotic treatment and a group receiving no treat-
ment. However, antibiotic susceptibility testing suggests 
that this approach may increase antibiotic resistance rates. 
However, our findings should be regarded with caution due 
to the small sample size analyzed that confers low level of 
statistical power.

























Isolated microorganisms in urine samples of AB episodes
Gram negative 102  113  81  107  
Escherichia coli 43 (36.1) 74 (54.0) 40 (43.5) 71 (55.4)
Klebsiella pneumoniae 37 (31.1) 24 (17.5) 26 (28.2) 24 (18.7)
Enterobacter aerogenes 6 (5.0) 2 (1.5) 5 (5.4) 2 (1.6)
Morganella morganii 4 (3.3) 2 (1.5) 2 (2.2) 0  
Proteus mirabillis 3 (2.5) 2 (1.5) 2 (2.2) 2 (1.6)
Other enterobacteriaceae 1 (0.8) 1 (0.7) 1 (1.1) 1 (0.7)
Pseudomonas aeruginosa 8 (6.7) 8 (5.8) 5 (5.4) 7 (5.5)
Gram positive 17  24  11  21  
 Enterococcus faecalis 13 (10.9) 19 (13.8) 8 (8.7) 17 (13.3)
Enterococcus faecium 1 (0.8) 1 (0.7) 1 (1.1) 1 (0.7)
Other Gram-positive microorganisms 3 (2.5) 4 (2.9) 2 (2.2) 3 (2.3)
Antibiotic susceptibility of isolated microorganisms in urine samples of AB episodes         
Ciprofloxacin resistant Gram-negative bacilli 61/102 (59.8) 73/113 (64.6) 48/81 (59.2) 62/107 (57.9)
Fosfomycin-resistant microorganisms 27/119 (22.7) 17/137 (12.4) 22/94 (23.4) 13/128 (10.2)
TMP-SMX–resistant enterobacteriaceae 78/94 (82.9) 77/105 (73.3) 62/76 (81.6) 67/100 (67.0)
Amoxicillin-clavulanate–resistant enterobacteriaceae 49/94 (52.1) 28/105 (26.7) 39/76 (51.3) 22/100 (22.0)
ESBL-producing enterobacteriaceae 23/94 (24.5) 14/105 (13.3) 16/76 (21.0) 11/100 (11.0)
MDR Pseudomonas aeruginosa 4/8 (50.0) 5/8 (62.5) 3/5 (60.0) 4/7 (57.1)
Antibiotics administered for asymptomatic bacteriuria episodes         
Cefuroxime 17 1 16 0
Amoxicillin-clavulanate 8 0 8 0
Ciprofloxacin 20 0 18 0
Fosfomycin 32 4 30 0
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Some retrospective studies have shown a higher incidence of 
subsequent AGP in KT recipients with AB, even though anti-
biotic treatment was given at the asymptomatic stage [26, 27]. 
Increased urine cytokines have also been documented in KT 
recipients with AB, suggesting that it may reflect an occult in-
flammatory process in the renal allograft [28, 29]. Given that 
AB in KT recipients has therefore been associated with the 
development of symptomatic infection, other retrospective 
studies have assessed the usefulness of giving antibiotics to 
KT recipients with AB. However, results have been conflicting. 
Although some authors have shown that antibiotic therapy 
may prevent symptomatic urinary infections [30], others have 
shown no differences in the progression toward symptomatic 
infection between treated and untreated AB episodes [31, 32]. 
Moreover, other research has observed a higher risk of symp-
tomatic infections in KT recipients receiving antibiotic therapy 
for AB [33]. In a recent RCT comparing antibiotic treatment 
with no treatment for AB in 112 KT recipients beyond the 
second month after transplantation, no differences were seen 
in the incidence of AGP or lower urinary tract infections [25].
It has been suggested that rejection and allograft dysfunc-
tion may be associated with urinary infections [4, 5, 8–11]. 
Nevertheless, antibiotic treatment of AB had no benefit in the 
incidence of rejection or allograft function within the first year 
after transplantation in our trial. Our findings concur with 
those encountered by other investigators [25, 31–33].
The selection of MDR organisms by the widespread use of 
antibiotics is of increasing concern. Given the high prevalence of 
AB in KT recipients, antibiotic treatment in these cases could sig-
nificantly affect antimicrobial resistance rates in this vulnerable 
population. We observed higher antibiotic resistance rates in the 
urine isolates of KT recipients who received treatment for AB more 
often than in those who did not receive treatment and this differ-
ence was not observed in the first episode of AB. However, this 
finding does not allow for firm assertions due to the small number 
of patients included. Moreover, this conflict with data from a pre-
vious study [25], in which higher antibiotic resistance rates were 
not seen in the isolates from KT recipients treated for AB.
Our study had some limitations that should be acknowl-
edged. A  percentage of KT during the study period were not 
eligible due to inclusion in other trials, mainly related to immu-
nosuppressive therapies. The planned study sample size was not 
achieved, in part, because the expected incidence of AGP was 
overestimated during study design. The low incidence of AGP 
in KT recipients documented in the study could be explained 
as only patients without urinary catheters were included and, 
in addition, KT recipients with urological complications were 
excluded. We know the small sample size limits any categorical 
conclusion about the results. Second, there was poor protocol 
compliance for KT recipients with AB assigned to the antibi-
otic treatment group, reflecting the inconvenience for attending 
physicians of considering and treating positive urine culture 
results in asymptomatic patients, especially when the utility 
of this practice is not clearly established. Protocol deviations 
were due to failure in revising urine culture results in some 
cases by the attending physician and, in a few cases, isolation of 
microorganisms without oral antibiotic treatment options.
In conclusion, our results suggest that antibiotic treatment of 
AB has no use in the prevention of AGP among KT recipients 
after urinary catheters are removed in the first year after trans-
plantation. In addition, antibiotic treatment of AB may increases 
antibiotic resistance in urine isolates. However, the study limita-
tions regarding sample size require further randomized studies 
to corroborate our findings.
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